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Abstract 
Angiogenesis induction is a hallmark of cancer. Antiangiogenic properties of Xanthohumol 
(XN), a naturally occurring prenylated chalcone from hops, have been widely reported. Here we 
describe the synthesis and study the antiangiogenic activity in vitro of a series of XN derivatives, 
where different substituents on the B-ring of the chalcone scaffold were inserted. The new XN 
derivatives inhibited human umbilical-vein endothelial cell (HUVEC) proliferation, adhesion, 
migration, invasion and their ability to form capillary-like structures in vitro at 10 µM 
concentration. The preliminary results indicate that the phenolic OH group in R, present in 
natural XN, is not necessary for having antiangiogenic activity. In fact, the most effective 
compound from this series, 13, was characterized by a para-methoxy group in R and a fluorine 
atom in R2 on B-ring. This study paves the way for future development of synthetic analogues of 
XN to be used as cancer angiopreventive and chemopreventive agents. 
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Abbreviations: XN, xanthohumol; HUVEC, human umbilical vein endothelial cells; EGCG, 
epigallocatechin-3-gallate; MOMCl, chloromethylmethyl ether; DEAD, diethyl 
azodicarboxylate; SAR, structure-activity relationship; FBS, foetal bovine serum; FITC, 
fluorescein isothiocyanate; DAPI, 4′,6-diamidine-2′-phenylindole dihydrochloride.  
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1. Introduction 
Angiogenesis refers to the formation of new blood vessels from pre-existing vasculature 1]. 
Physiological angiogenesis is necessary for key processes such as wound healing and tissue 
regeneration and repair. In pathological conditions, including cardiovascular diseases, diabetes, 
cancer, and other pathologies associated with chronic inflammation, angiogenesis represent a 
relevant hallmark contributing to disease insurgence and progression. Therefore, the induction of 
new blood vessels is a necessary condition for tumors to recruit oxygen, nutrients and 
disseminate to distant sites. Strategies aimed at blocking or delaying tumor angiogenesis, have 
been employed both in therapeutic and (chemo) prevention settings and promising results have 
been obtained in pre-clinical models and in the clinics [2, 3]. Cancer chemoprevention offers the 
possibility of long-term low toxic treatments that could keep initial tumors at bay, delaying their 
progression to a clinically relevant tumor 4-6]. Many chemopreventive agents are directly 
derived from natural sources (phytochemicals) that have been reported to exert anti-proliferative, 
pro-apoptotic, antioxidant and anti-inflammatory activities 7]. We have demonstrated that many 
of these phytochemical derived agents act also as anti-angiogenic and anti-inflammatory drugs, a 
concept we named “angioprevention” 8-10]. Substantial attention has been addressed to 
flavonoids and their synthetic precursors, chalcones, a class of polyphenolic compounds that, 
within their wide range of activity, also exhibit anti-angiogenic properties 11]. During the last 
decades, the prenylated chalcone Xanthohumol (XN, 1, Fig. 1) has emerged as a cancer 
chemopreventive agent 12]. It is the major prenylated chalcone present in the female 
inflorescences of the hop plant Humulus lupulus L. (Cannabaceae) employed in the brewing 
process to preserve and to add bitterness and flavor to beer. The beneficial properties of hops are 
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well known from ancient times and have been used in traditional medicines since the IX century. 
Xanthohumol was first isolated by Power in 1913 and its structure was elucidated in 1957 by 
Verzele 13]. However, only in the last decades, we assisted to an increasing interest to this 
molecule, since it is endowed with multiple biological activities including anti-diabetic, anti-
inflammatory, anti-oxidant, anti-cancer, anti-invasive, and anti-angiogenic activities 14]. Given 
the promising results from in vitro and in vivo preclinical studies that have pointed out the 
numerous benefits exerted by XN, clinical trials are currently being developed evaluating the 
feasibility of XN treatment in the context of metabolic syndrome and prevention of DNA 
damage (https://clinicaltrials.gov/) 15]. We showed that XN has stronger anti-angiogenic 
activity as compared to the green tea flavonoid epigallocatechin-3-gallate (EGCG) 16]. Due to 
the multiple beneficial activities of XN, we were interested in determining whether chemical 
modification of the XN-scaffold resulted in more effective inhibition of angiogenesis, to identify 
novel potential chemopreventive agents. Therefore, we developed of a series of novel synthetic 
analogues of XN, compounds 2-14 17], reported in Table 1. A series of XN analogues has been 
recently synthesized and shown to have toxicity toward HeLa cells by inhibiting the 
selenoprotein thioredoxin reductases (TrxRs) 18]. We chose to replace the phenolic group on B-
ring of the XN (Fig. 1) with several substituents endowed with different electronic and steric 
properties such as halogens, methoxy or nitro groups, to evaluate the impact of these 
modifications on antiangiogenic activity. The prenyl group on A-ring was left unchanged, since 
previous studies 19] confirmed its importance for antiangiogenic activity. Derivatives 3, 5, 7, 10 
and 13 were synthesized and tested together with some analogues MOM-protected on A-ring, 
defined compounds 2, 4, 6, 8, 9, 11, 12 and 14. Here, we compared the antiangiogenic effects of 
XN and our novel synthetic derivatives in vitro, where human umbilical vein endothelial cells 
 
5
(HUVEC) were used as a model for cell proliferation, apoptosis, cell adhesion, migration, 
invasion and formation of capillary-like structures.  
 
 
Fig. 1. Natural product Xanthohumol (XN) and its new synthetic analogues. 
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Table 1. Structure of the new synthetic XN analogues 2-14. 
 
Compd R R1 R2 R3 R4 
2 Cl Cl H MOM H 
3 Cl Cl H H H 
4 F H H MOM H 
5 F H H H H 
6 H H F MOM H 
7 H H F H H 
8 OCH3 F H MOM MOM 
9 OCH3 F H MOM H 
10 OCH3 F H H H 
11 OCH3 H F MOM MOM 
12 OCH3 H F MOM H 
13 OCH3 H F H H 
14 NO2 H H MOM H 
 
 
2. Results and discussion. 
2.1. Chemistry. 
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The novel synthetic XN analogues have been synthesized following the synthetic approach 
previously reported for the synthesis of XN and its natural derivatives [20, 21] and depicted in 
Scheme 1. 
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Scheme 1. Synthesis of XN analogues 2-14. Reagents and conditions: (a) MOMCl, DIPEA, CH2Cl2, 
rt, 6 h, 57%; (b) 3-methyl-2-butene-1-ol, DEAD, PPh3, THF, rt, 18 h, 60%; (c) N,N-dimethylaniline, 200 
°C, 4 h, 42%; (d) (CH3O)SO2, K2CO3, acetone, reflux, 6 h, 65%; (e) the appropriate substituted 
benzaldehyde, aqueous NaOH, MeOH, reflux, 4 h, 24-62%; (f) HCl, MeOH/H2O, 45 °C, 45 min, 7-77%. 
 
Partial methoxymethyl (MOM) protection of commercially available 2,4,6-
trihydroxyacetophenone with chloromethylmethyl ether (MOMCl) yielded derivative 16. The 
prenyl group has been then introduced using two subsequent steps: a Mitsunobu reaction with 
prenyl alcohol to form the prenyl ether 17 followed by a Claisen rearrangement that provided 
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prenylated acetophenone 18. The Mitsunobu condensation of phenol 16 with prenyl alcohol was 
conducted in the presence of diethyl azodicarboxylate (DEAD) and triphenylphosphine (PPh3) in 
THF (60% yield), then phenol 18 was obtained by treatment of 17 with N,N-dimethylaniline, at 
200 °C for 4 h (42% yield). The phenolic hydroxyl group was then converted in the methoxy 
function by reaction with dimethyl sulfate in the presence of K2CO3 (65%yield) and the 
derivative 19 thus obtained was used in a Claisen-Schmidt condensation with diverse substituted 
benzaldehydes to build up the chalcone scaffold. When 2,4 and 3,4-difluoro benzaldehydes have 
been used, the chalcones obtained showed in 4 position a methoxy moiety, due to fluorine 
displacement reaction occurring in the reaction conditions (NaOH aq. in MeOH, at 65 °C). 
Finally, treatment of chalcones 20-23, 8, 11, with HCl in MeOH/H2O under controlled 
temperature and acidity conditions, allowed to obtain the deprotected XN analogues 3, 5, 7, 10, 
13 together with MOM mono-protected derivatives 2, 4, 6, 9, 12-14. Deprotected and mono-
protected derivatives were separated by flash chromatography. 
 
2.2. Biological activity. 
In preliminary experiments the anti-angiogenic activity of XN was compared to the one of green 
tea epigallocatechin-3-gallate (EGCG), extensively described in literature as anti-angiogenic 
flavonoid, by analyzing human endothelial cells proliferation, viability, cell functions, the ability 
to interfere with migration, invasion and the capability to form capillary-like networks on matrix 
basement membrane (data not shown) [16]. All our analysis pointed out a more powerful anti-
angiogenic-related activities of XN than EGCG. We therefore employed in all the assays 
unmodified original Xantohumol molecule as a positive control for the synthetic derivatives. 
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2.2.1. Effects of XN derivatives on HUVE cell proliferation and viability. 
The newly synthesized compounds (4-14, Table 1) were first tested for cytotoxicity on human 
umbilical vein endothelial cells (HUVECs). Compounds 2 and 3 were considered unfit for 
testing due to some solubility issues. We treated HUVECs with increasing concentrations of XN 
(the positive control for antiangiogenesis) and its derivatives ranging from 1 µM to 20 µM for 
24, 48, 72 and 96 h. Cell viability was then assessed by the MTT assay and cell death was 
demonstrated by Annexin-V/7-AAD double-staining and quantified on a flow cytometry. We 
observed that most of the XN derivatives inhibited HUVEC proliferation in a dose-dependent 
and time-dependent manner (Fig. 2). Since XN and many of its derivatives, such as 13 and 14 
showed a relevant toxicity at 20 µM (Fig. 3), we used the 10 µM dose for the subsequent 
experiments and consistent with previous publications 16, 22]. At the 10 µM concentration and 
the 96h time point, several derivatives statistically inhibited HUVE cell growth as compared to 
XN alone: in particular 8 and 11 (Fig. 2). Noteworthy, derivative 14 was the only compound to 
show toxicity at 10 µM dose, as indicated by increased apoptosis on HUVECs (Fig. 3). 
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Figure 2. Effects of XN derivatives on endothelial cell proliferation in vitro –XN and XN derivatives 
interfere with endothelial cell (HUVEC) proliferation, as assessed by MTT assay. Results are showed as 
Mean  SEM; *p <0.05, ***p<0.001 compared to XN alone. “Vehicle” indicates cells treated with 
vehicle (DMSO in the medium). 
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Figure 3. Effects of XN derivatives on endothelial cell viability in vitro - Flow cytometry analysis 
showed that 24 h treatment of endothelial cells with 20 µM XN derivatives resulted in increased rates of 
apoptotic (AnnexinV+7-AAD-/+) cells. “Vehicle” indicates cells treated with vehicle (DMSO in the 
medium). Results are showed as Mean  SEM.  
 
These results suggest that the presence of a MOM-protective group in R4 positively impacts on 
the ability to block cell proliferation, considering that 8 and 11 (the only two derivatives of the 
series bearing two MOM-protecting groups on A-ring) are the most potent inhibitors of HUVE 
cell growth (Fig. 2). Moreover, the introduction of a strong electron-withdrawing group such as a 
nitro group in R on B-ring seems to cause toxicity, as shown by the increased apoptosis on 
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HUVECs given by compound 14 already at 10 µM concentration. Finally, only compound 12 
characterized by a para-methoxy substituent on B-ring, a fluorine atom in R2 and a MOM-group 
in R3 position was not able to affect endothelial cell growth. 
 
2.2.2. Effect of XN derivatives on HUVE cell adhesion, migration and invasion  
Since adhesion, migration and invasion are crucial steps for angiogenesis, we also investigated 
the abilities of XN and its derivatives to inhibit these processes. We observed that XN and its 
synthetic derivatives were able to decrease HUVEC adhesion compared with the nontreated 
control (FBS 10% with dissolved vehicle, DMSO) (Fig. 4A). However, only one of the synthetic 
derivatives, 13, was statistically more active than the parent compound XN. Comparable results 
were obtained in terms of migration with XN and its derivatives (except for 12) which were able 
to decrease HUVEC migration (Fig. 4B) compared with the control. Again, 13 showed 
significantly greater inhibition than XN, along with compound 5. In the invasion assay, XN and 
its derivatives (except for 9 and 12) showed statistical differences compared to that of the control 
(Fig. 4C). However, in this case, none of the derivatives showed significantly more activity 
compared to the parent compound XN.  
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Figure 4. Effects of xanthohumol derivatives on HUVE cell adhesion, invasion and migration. XN 
and XN derivatives at 10 µM concentration can interfere with crucial steps of angiogenesis by decreasing 
HUVEC A) adhesion B) migration and C) invasion, as compared to vehicle-treated cells. “Vehicle” 
indicates cells treated with vehicle (DMSO in the medium). Results are showed as Mean  SEM. *p 
<0.05; **p<0.001; ***p<0.001 as indicated by the bars.  
 
These results point out the importance of a phenolic OH group in R3 together with a fluorine 
atom on ring-B for having inhibitory activity on cell migration (see activity of 5 vs 4 and of 13 
vs 12, Fig. 4B). In particular, compound 13, characterized by a para-methoxy substituent on B-
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ring and a fluorine atom in R2 position, showed the best activity on migration and adhesion 
inhibition on HUVECs also compared to XN. 
 
2.2.3. Effect of XN derivatives on morphogenesis in vitro 
When cultured on a membrane-basement matrix layer, HUVE cells form capillary-like networks 
within 6 h in vitro, mimicking the events occurring during vessel network formation in vivo. We 
evaluated the ability of XN derivatives to effect HUVEC morphogenesis in vitro at 10 µM 
concentration. We observed that all the XN derivatives were able to decrease the formation of 
capillary-like structures in a statistically significant manner as compared to the control (FBS 
10% without vehicle) (Fig. 5). Noteworthy, almost all XN derivatives were more potent than the 
parental compound XN for all parameters considered, and among them 5, 8 and even more so 13 
showed statistically significant differences in number of master segments.  
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Figure 5. Effects of XN derivatives on HUVEC morphogenesis – Following 6 h treatment, XN and all 
XN derivatives at 10 µM concentration can inhibit HUVEC ability to form capillary-like structures on 
matrigel compared with vehicle-treated cells. SFM: cells treated with serum-free EGM-2 medium as a 
negative control. FBS 10%: cells treated with medium containing 10% FBS without vehicle. “Vehicle” 
indicates cells treated with vehicle (DMSO in the medium). Results are showed as Mean  SEM. *p 
<0.05; **p<0.001; ***p<0.001 as indicated by the bars. 
 
Also in this assay, the best activity results were given by compound 13, characterized by a para-
methoxy substituent on B-ring and a fluorine atom in R2 position. Taken together, all these data 
suggest that the new XN derivatives exert antiangiogenic activities that can be even higher than 
the XN ones.  
3. Conclusions. 
A new series of synthetic derivatives of XN has been prepared and their effects on angiogenesis 
have been evaluated in comparison with XN ones. In particular, compounds 4-14 have been 
tested in vitro on cell proliferation, apoptosis, cell adhesion, migration, invasion and 
morphogenesis with HUVE cells at 10 µM concentration. Despite the limited number of 
derivatives synthesized in the present study, some comments about structure-activity 
relationships (SAR) can be made. The results obtained so far suggest the importance of a 
phenolic OH group in R3 on A-ring together with a fluorine atom on B-ring for having inhibitory 
activity on cell migration (see activity of 5 vs 4 and of 13 vs 12, Fig. 4B). The presence of a 
MOM-protective group in R4 seems to positively influence the ability to block cell proliferation, 
considering that 8 and 11 are the most potent inhibitors of HUVE cell growth (Fig. 2). Moreover, 
the introduction of a nitro group in R on B-ring seems to cause toxicity, as shown by the 
increased apoptosis on HUVECs given by compound 14 already at 10 µM. Noteworthy, the 
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phenolic OH group in R, present in natural XN, does not seem necessary for having 
antiangiogenic activity. In fact, among all synthesized compounds, the best activity results were 
exhibited by compound 13, which was the strongest inhibitor of cell adhesion, migration and 
morphogenesis even compared to XN. This derivative is characterized by a para-methoxy group 
in R and a fluorine atom in R2 on B-ring. Given the different activity between 13 and its 
analogue bearing a fluorine in R1, compound 10, the position of F substitution on B-ring seems 
to be determinant for activity.  
Overall, these preliminary data highlight that the newly synthesized XN derivatives may 
represent relevant compounds able to affect crucial steps of angiogenesis. Further studies must 
be conducted to assess the pharmacokinetic properties of the most promising compounds in 
comparison with naturally produced XN. 
 
4. Experimental section 
4.1. Chemistry. Melting points were determined on a Kofler hotstage apparatus and are 
uncorrected. 1H, 13C and 19F NMR spectra were determined with a Varian Gemini 200 MHz 
spectrometer or a Bruker Avance III HD 400 MHz spectrometer. Chemical shifts (δ) are reported 
in parts per million and coupling constants (J) are given in hertz (Hz). The following 
abbreviations are used: singlet (s), doublet (d), triplet (t), double-doublet (dd), double-triplet (dt), 
broad (br) and multiplet (m). Chromatographic separations were performed on silica gel columns 
by flash column chromatography (Kieselgel 40, 0.040–0.063 mm; Merck) or using ISOLUTE 
Flash Si II cartridges (Biotage). Reactions were followed by thin-layer chromatography (TLC) 
on Merck aluminum silica gel (60 F254) sheets that were visualized under a UV lamp. 
Evaporation was performed in vacuo (rotating evaporator). Sodium sulfate was always used as 
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the drying agent. Commercially available chemicals were purchased from Sigma-Aldrich (Milan, 
Italy). Elemental analysis has been used to determine the purity of target compounds. Analytical 
results are within ± 0.40% of the theoretical values. 
4.2. 2′-Hydroxy-4′,6′-dimethoxymethylacetophenone (16).  
To an ice-cooled suspension of 2′,4′,6′-trihydroxyacetophenone monohydrate (2.00 g, 10.74 
mmol) in 21.50 mL of CH2Cl2, N,N-diisopropylethylamine (5.60 mL, 32.22 mmol) and then 
dropwise MOMCl (2.40 mL, 32.22 mmol) were added. The reaction was gradually allowed to 
reach room temperature and stirred for 6 h. The reaction was quenched with aqueous saturated 
NH4Cl solution (20 mL). The resulting mixture was extracted with CH2Cl2/H2O (1:1). The 
organic layers were combined, dried over Na2SO4, filtered, and evaporated. The yellowish 
residue was purified by flash chromatography (n-hexane/EtOAc 6:1) using a Isolute Flash Si II 
cartridge to afford 16 23] as a colorless oil (1.57 g, 57% yield). 1H NMR (200 MHz, CDCl3) δ: 
2.65 (s, 3H), 3.47 (s, 3H), 3.52 (s, 3H), 5.17 (s, 2H), 5.25 (s, 2H), 6.24 (d, J = 2.4 Hz, 1H), 6.27 
(d, J = 2.4 Hz, 1H). 
4.3. 4′,6′-Dimethoxymethyl-2′-(3-methylbut-2-en-1-yloxy)acetophenone (17).  
To an ice-cooled solution of 16 (917 mg, 3.57 mmol) in 18 mL of dry THF, PPh3 (1.123 g, 
4.30 mmol) and 3-methyl-2-buten-1-ol (0.54 mL, 5.35 mmol) were added. Diethyl 
azodicarboxylate (DEAD) (0.90 mL, 5.71 mmol), was added dropwise and the resulting solution 
was allowed to reach room temperature and stirred for 18 h. The solvent was evaporated, the 
residue suspended in ether and the solid filtered. The filtrate was evaporated and the residue was 
purified by silica gel flash chromatography (n-hexane/EtOAc 6:1) affording 17 24] as a 
colorless oil (684 mg, 60% yield). 1H NMR (200 MHz, CDCl3) δ: 1.70 (s, 3H), 1.75 (s, 3H), 2.47 
 
18
(s, 3H), 3.45 (s, 3H), 3.47 (s, 3H), 4.49 (d, J = 6.6 Hz, 2H), 5.12 (s, 2H), 5.15 (s, 2H), 5.40 (t, J = 
6.6 Hz, 1H), 6.30 (d, J = 1.8 Hz, 1H), 6.43 (d, J = 1.8 Hz, 1H). 
4.4. 2′,4′-Dimethoxymethyl-6′-hydroxy-3′-(3-methylbut-2-en-1-yloxy)-acetophenone (18). 
Intermediate 17 (680 mg, 2 mmol) was dissolved in 21 mL of N,N-dimethylaniline and heated 
at 200 °C for 4 h. Ethyl acetate (100 mL) was added and the mixture washed with 1 N HCl (2 × 
100 mL). The organic layer was dried over Na2SO4, filtered, and evaporated. The residue was 
purified by flash chromatography (n-hexane/EtOAc 20:1) using a Isolute Flash Si II cartridge to 
afford 18 24] as yellow oil (275 mg, 42% yield). 1H NMR (200 MHz, CDCl3) δ: 1.68 (s, 3H), 
1.76 (s, 3H), 2.70 (s, 3H), 3.30 (d, J = 6.6 Hz, 2H), 3.45 (s, 3H), 3.51 (s, 3H), 4.95 (s, 2H), 5.12-
5.14 (m, 1H), 5.21 (s, 2H), 6.47 (s, 1H). 
4.5. 2′,4′-Dimethoxymethyl-6′-methoxy-3′-(3-methylbut-2-en-1-yloxy)-acetophenone (19).  
To a stirred solution of 18 (270 mg, 0.83 mmol) in 17 mL of acetone, K2CO3 (230 mg, 1.66 
mmol) was slowly added and then dimethyl sulfate (0.15 mL, 1.66 mmol). The reaction mixture 
was refluxed for 6 h, allowed to cool to room temperature, and quenched with 16 mL of NH4OH. 
Then, it was extracted with CH2Cl2/H2O (1:1) 3 × 30 mL. The organic layers were combined, 
dried over Na2SO4, filtered and evaporated. The residue was purified by flash chromatography 
(n-hexane/EtOAc 8:1) using a Isolute Flash Si II cartridge to afford 19 20] as yellow oil (183 
mg, 65% yield). 1H NMR (200 MHz, CDCl3) δ: 1.66 (s, 3H), 1.74 (s, 3H), 2.49 (s, 3H), 3.30 (d, 
J = 6.6 Hz, 2H), 3.47 (s, 3H), 3.48 (s, 3H), 3.79 (s, 3H), 4.90 (s, 2H), 5.12-5.14 (m, 1H), 5.20 (s, 
2H), 6.54 (s, 1H). 
4.6. General Procedure to Synthesize Chalcones 8, 11, 20-23. 
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To a stirred solution of 19 (1 eq) and the properly substituted benzaldehyde (1 eq) in MeOH 
(40 mL/mmol), 10% NaOH aqueous solution (2 mL/mmol) was added and the reaction mixture 
was refluxed for 4 h. The solution was then extracted with EtOAc/H2O (1:1). The combined 
organic layers were dried over Na2SO4, filtered, and evaporated. The residue was purified by 
flash chromatography affording the desired compounds 8, 11, 20-23. 
4.7. (E)-3-(3-fluoro-4-methoxyphenyl)-1-(6-methoxy-2,4-bis(methoxymethoxy)-3-(3-
methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (8).  
The title compound was prepared according the general procedure, using 3,4 
difluorobenzaldehyde (42 mg, 0.29 mmol). The crude was purified by flash chromatography (n-
hexane/EtOAc 10:1) using a Isolute Flash Si II cartridge to afford 8 as yellow oil (57 mg, 41% 
yield). 1H NMR (200 MHz, CDCl3) δ: 1.70 (s, 3H), 1.78 (s, 3H), 3.37 (d, J = 6.8 Hz, 2H), 3.45 
(s, 3H), 3.52 (s, 3H), 3.79 (s, 3H), 3.94 (s, 3H), 4.93 (s, 2H), 5.15-5.22 (m, 1H), 5.26 (s, 2H), 
6.61 (s, 1H), 6.89 (d, J = 15.7 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 7.25-7.38 (m, 3H). 13C NMR 
(100 MHz, CDCl3) δ: 17.9, 22.1, 25.8, 55.9, 56.2, 56.2, 57.4, 89.3, 94.2, 101.0, 108.3, 109.0, 
113.9, 114.3, 123.6, 126.4, 126.8, 129.0, 131.4, 141.0, 150.2, 153.6 (d, 1JC-F = 246.6 Hz)), 161.5, 
162.0, 164.3, 193.0. Elemental Analysis for C26H31FO7 calculated: % C, 65.81; % H, 6.58; 
found: % C, 65.93; % H, 6.76. 
4.8. (E)-3-(2-fluoro-4-methoxyphenyl)-1-(6-methoxy-2,4-bis(methoxymethoxy)-3-(3-
methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (11).  
The title compound was prepared according the general procedure, using 2,4 
difluorobenzaldehyde (114 mg, 0.80 mmol). The crude was purified by flash chromatography (n-
hexane/EtOAc 8:1) using a Isolute Flash Si II cartridge to afford 11 as yellow oil (118 mg, 31% 
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yield). 1H NMR (200 MHz, CDCl3) δ: 1.68 (s, 3H), 1.77 (s, 3H), 3.36 (d, J = 6.6 Hz, 2H), 3.44 
(s, 3H), 3.51 (s, 3H), 3.77 (s, 3H), 3.83 (s, 3H), 4.92 (s, 2H), 5.14-5.21 (m, 1H), 5.24 (s, 2H), 
6.60 (s, 1H), 6.65-6.74 (m, 2H), 6.98 (d, J = 16.0 Hz, 1H), 7.46-7.56 (m, 2H). 13C NMR (100 
MHz, CDCl3) δ: 18.0, 23.1, 25.8, 55.8, 56.1, 56.2, 57.6, 89.2, 94.5, 100.9, 101.9, 110.8, 111.1, 
115.8, 122.8, 128.7, 130.0, 131.3, 136.7, 161.0, 162.6 (d, 1JC-F = 254.0 Hz), 162.6, 162.7, 164.3, 
194.1. 19F NMR (376 MHz, CDCl3) δ: -111.32. Elemental Analysis for C26H31FO7 calculated: % 
C, 65.81; % H, 6.58; found: % C, 66.17; % H, 6.63. 
4.9. (E)-3-(3,4-dichlorophenyl)-1-(6-methoxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-
2-en-1-yl)phenyl)prop-2-en-1-one (20).  
The title compound was prepared according the general procedure, using 3,4-
dichlorobenzaldehyde (93 mg, 0.53 mmol). The crude was purified by flash chromatography (n-
hexane/EtOAc 12:1) using a Isolute Flash Si II cartridge to afford 20 as a semisolid yellow oil 
(163 mg, 62% yield). 1H NMR (200 MHz, CDCl3) δ: 1.68 (s, 3H), 1.76 (s, 3H), 3.34 (d, J = 6.8 
Hz, 2H), 3.41 (s, 3H), 3.50 (s, 3H), 3.77 (s, 3H), 4.90 (s, 2H), 5.14-5.21 (m, 1H), 5.24 (s, 2H), 
6.59 (s, 1H), 6.96 (d, J = 15.9 Hz, 1H), 7.32 (d, J = 15.9 Hz, 1H), 7.38-7.47 (m, 2H), 7.60 (d, J = 
1.8 Hz, 1H). 
4.10. (E)-3-(4-fluorophenyl)-1-(6-methoxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-
en-1-yl)phenyl)prop-2-en-1-one (21).  
The title compound was prepared according the general procedure, using 4-
fluorobenzaldehyde (47 µL, 0.44 mmol). The crude was purified by flash chromatography (n-
hexane/EtOAc 12:1) using a Isolute Flash Si II cartridge to afford 21 as a semisolid yellow oil 
(47 mg, 24% yield). 1H NMR (200 MHz, CDCl3) δ: 1.68 (s, 3H), 1.76 (s, 3H), 3.34 (d, J = 7.1 
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Hz, 2H), 3.42 (s, 3H), 3.50 (s, 3H), 3.76 (s, 3H), 4.90 (s, 2H), 5.14-5.22 (m, 1H), 5.24 (s, 2H), 
6.59 (s, 1H), 6.92 (d, J = 16.0 Hz, 1H), 7.06 (m, 2H), 7.38 (d, J = 16.0 Hz, 1H), 7.49-7.56 (m, 
2H). 
4.11. (E)-3-(2-fluorophenyl)-1-(6-methoxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-
en-1-yl)phenyl)prop-2-en-1-one (22).  
The title compound was prepared according the general procedure, using 2-fluorobenzaldehyde 
(275 mg, 0.81 mmol). The crude was purified by flash chromatography (n-hexane/EtOAc 12:1) 
using a Isolute Flash Si II cartridge to afford 22 as yellow oil (170 mg, 47% yield). 1H NMR 
(200 MHz, CDCl3) δ: 1.68 (s, 3H), 1.79 (s, 3H), 3.35 (d, J = 6.9 Hz, 2H), 3.43 (s, 3H), 3.49 (s, 
3H), 3.82 (s, 3H), 4.93 (s, 2H), 5.19-5.24 (m, 1H), 5.28 (s, 2H), 6.50 (s, 1H), 7.00-7.11 (m, 2H), 
7.18 (d, J = 16.0 Hz, 1H), 7.29-7.36 (m, 1H), 7.50-7.60 (m, 2H).  
4.12. (E)-1-(6-methoxy-2,4-bis(methoxymethoxy)-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-
nitrophenyl)prop-2-en-1-one (23).  
The title compound was prepared according the general procedure, using 4-nitrobenzaldehyde 
(201 mg, 1.33 mmol). The crude was purified by flash chromatography (n-hexane/EtOAc 6:1) 
using a Isolute Flash Si II cartridge to afford 23 as yellow oil (274 mg, 44% yield). 1H NMR 
(200 MHz, CDCl3) δ: 1.69 (s, 3H), 1.77 (s, 3H), 3.36 (d, J = 6.6 Hz, 2H), 3.42 (s, 3H), 3.48 (s, 
3H), 3.79 (s, 3H), 4.92 (s, 2H), 5.16-5.24 (m, 1H), 5.26 (s, 2H), 6.61 (s, 1H), 7.11 (d, J = 16.2 
Hz, 1H), 7.48 (d, J = 16.2 Hz, 1H), 7.66-7.71 (m, 2H), 8.20-8.26 (m, 2H). 
4.13. General Procedure to Synthesize Xanthohumol analogues 2-7, 9, 10, 12-14. 
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To a stirred solution of chalcone in MeOH/H2O, concentrated HCl was added until pH 1 and 
the mixture was heated at 45 °C for 45 min. The reaction mixture was then extracted with 
EtOAc/H2O, the organic layers were combined, dried over Na2SO4, filtered, and evaporated at 20 
°C. The residue was purified by flash chromatography affording the desired compounds 2-7, 9, 
10, 12-14. 
4.14. (E)-3-(3,4-dichlorophenyl)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)-3-(3-
methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (2) and (E)-3-(3,4-dichlorophenyl)-1-(2,4-
dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (3). 
The title compounds were prepared according the general procedure, starting from compound 
20 (62 mg, 0.12 mmol). The residue was purified by flash chromatography (n-hexane/EtOAc 
7:1) using a Isolute Flash Si II cartridge to afford 2 (31 mg, 57% yield) as orange solid and 3 (9 
mg, 18% yield) as yellow solid. (2) mp 105-107 °C.  1H NMR (400 MHz, CDCl3) δ: 1.67 (s, 3H), 
1.79 (s, 3H), 3.32 (d, J = 7.1 Hz, 2H), 3.49 (s, 3H), 3.92 (s, 3H), 5.19-5.24 (m, 1H), 5.27 (s, 2H), 
6.24 (s, 1H), 7.40 (dd, J1 = 8.3 Hz, J2 = 2.0 Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 15.6 
Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.81 (d, J = 15.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 
17.7, 21.6, 25.8, 55.9, 56.2, 89.1, 93.9, 106.9, 111.0, 122.5, 127.3, 129.6, 129.6, 130.8, 131.4, 
133.1, 133.6, 135.7, 138.9, 160.9, 161.3, 164.3, 192.5. Elemental Analysis for C23H24Cl2O5 
calculated: % C, 61.21; % H, 5.36; found: % C, 61.49; % H, 5.48. (3) mp 62-64 °C. 1H NMR 
(400 MHz, CDCl3) δ: 1.78 (s, 3H), 1.83 (s, 3H), 3.40 (d, J = 6.3 Hz, 2H), 3.90 (s, 3H), 5.26-5.32 
(m, 1H), 5.95 (s, 1H), 6.26 (br, 1H), 7.39-7.48 (m, 2H), 7.60-7.66 (m, 2H), 7.84 (d, J = 15.8 Hz, 
1H). 13C NMR (100 MHz, CDCl3) δ: 18.0, 21.7, 25.9, 56.0, 91.4, 106.2, 106.4, 121.7, 127.4, 
129.7, 129.8, 130.9, 133.2, 133.8, 135.9, 136.3, 139.1, 161.3, 162.5, 165.3, 192.3. Elemental 
Analysis for C21H20Cl2O4 calculated: % C, 61.93; % H, 4.95; found: % C, 62.24; % H, 5.12. 
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4.15. (E)-3-(4-fluorophenyl)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)-3-(3-
methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (4) and (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-
methylbut-2-en-1-yl)phenyl)-3-(4-fluorophenyl)prop-2-en-1-one (5). 
The title compounds were prepared according the general procedure, starting from compound 21 
(91 mg, 0.20 mmol). The residue was purified by flash chromatography (n-hexane/EtOAc 7:1) 
using a Isolute Flash Si II cartridge to afford 4 (6 mg, 7% yield) as orange solid and 5 (29 mg, 
41% yield) as yellow solid. (4) mp 80-82 °C. 1H NMR (400 MHz, CDCl3) δ: 1.67 (s, 3H), 1.79 
(s, 3H), 3.33 (d, J = 7.1 Hz, 2H), 3.50 (s, 3H), 3.92 (s, 3H), 5.20-5.24 (m, 1H), 5.27 (s, 2H), 6.24 
(s, 1H), 7.07-7.11 (m, 2H), 7.56-7.60 (m, 2H), 7.72 (d, J = 15.6 Hz, 1H), 7.79 (d, J = 15.6 Hz, 
1H). 13C NMR (100 MHz, CDCl3) δ: 17.9, 21.8, 25.9, 56.0, 56.3, 89.3, 94.0, 107.2, 111.1, 116.1 
(d, 2JC-F = 21.8 Hz), 122.7, 127.7, 130.2, 131.4, 132.0, 140.8, 161.0, 161.2, 163.8 (d, 1JC-F = 
250.9 Hz), 164.4, 193.1. Elemental Analysis for C23H25FO5 calculated: % C, 68.99; % H, 6.29; 
found: % C, 69.13; % H, 6.13. (5) mp 167-169 °C. 1H NMR (400 MHz, CDCl3) δ: 1.77 (s, 3H), 
1.83 (s, 3H), 3.40 (d, J = 7.2 Hz, 2H), 3.89 (s, 3H), 5.27-5.31 (m, 1H), 5.95 (s, 1H), 6.30 (br, 
1H), 7.07-7.11 (m, 2H), 7.56-7.60 (m, 2H), 7.73 (d, J = 15.6 Hz, 1H), 7.82 (d, J = 15.6 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ: 18.0, 21.7, 25.9, 55.9, 91.3, 106.2, 106.5, 116.1 (d, 2JC-F = 21.9 
Hz), 121.8, 127.7, 130.2, 132.0, 136.0, 140.9, 161.3, 162.2, 163.9 (d, 1JC-F = 250.0 Hz), 165.3, 
192.8. Elemental Analysis for C21H21FO4 calculated: % C, 70.77; % H, 5.94; found: % C, 70.99; 
% H, 5.70. 
4.16. (E)-3-(2-fluorophenyl)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)-3-(3-
methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (6) and (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-
methylbut-2-en-1-yl)phenyl)-3-(2-fluorophenyl)prop-2-en-1-one (7). 
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The title compounds were prepared according the general procedure, starting from compound 22 
(170 mg, 0.39 mmol). The residue was purified by flash chromatography (n-hexane/EtOAc 10:1) 
using a Isolute Flash Si II cartridge to afford 6 (86 mg, 54% yield) and 7 (13 mg, 9% yield) as 
yellow-orange solids. (6) mp 91-93 °C. 1H NMR (400 MHz, CDCl3) δ: 1.67 (s, 3H), 1.79 (s, 3H), 
3.33 (d, J = 7.1 Hz, 2H), 3.49 (s, 3H), 3.91 (s, 3H), 5.20-5.25 (m, 1H), 5.27 (s, 2H), 6.24 (s, 1H), 
7.08-7.19 (m, 2H), 7.31-7.37 (m, 1H), 7.55-7.60 (m, 1H), 7.83 (d, J = 15.8 Hz, 1H), 7.97 (d, J = 
15.8 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 17.9, 21.7, 25.9, 55.9, 56.3, 89.2, 94.0, 107.2, 
111.1, 116.3 (d, 2JC-F = 22.0 Hz), 122.8, 123.8, 124.5, 129.8, 130.7, 131.3, 131.4, 134.6, 161.1, 
161.3, 161.8 (d, 1JC-F = 254.0 Hz), 164.4, 193.3. 19F NMR (376 MHz, CDCl3) δ: -113.85. 
Elemental Analysis for C23H25FO5 calculated: % C, 68.99; % H, 6.29; found: % C, 69.28; % H, 
6.62. (7) mp 157-159 °C. 1H NMR (400 MHz, CDCl3) δ: 1.77 (s, 3H), 1.83 (s, 3H), 3.39 (d, J = 
7.2 Hz, 2H), 3.88 (s, 3H), 5.26-5.30 (m, 1H), 5.94 (s, 1H), 6.40 (br, 1H), 7.08-7.19 (m, 2H), 
7.31-7.37 (m, 1H), 7.56 -7.60 (m, 1H), 7.84 (d, J = 15.8 Hz, 1H), 8.00 (d, J = 15.8 Hz, 1H). 13C 
NMR (100 MHz, CDCl3) δ: 18.0, 21.7, 25.9, 55.8, 91.3, 106.3, 106.5, 116.3 (d, 2JC-F = 22.0 Hz), 
121.8, 123.8, 124.5, 129.8, 130.6, 131.3, 134.7, 135.8, 161.4, 161.7 (d, 1JC-F = 253.9 Hz), 162.3, 
165.3, 192.9. 19F NMR (376 MHz, CDCl3) δ: -113.89. Elemental Analysis for C21H21FO4 
calculated: % C, 70.77; % H, 5.94; found: % C, 70.54; % H, 5.73. 
4.17. (E)-3-(3-fluoro-4-methoxyphenyl)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)-3-
(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (9) (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-
methylbut-2-en-1-yl)phenyl)-3-(3-fluoro-4-methoxyphenyl)prop-2-en-1-one (10). 
The title compounds were prepared according the general procedure, starting from compound 
8 (275 mg, 0.58 mmol). The residue was purified by silica gel flash chromatography (n-
hexane/EtOAc 4:1) to afford 9 (24 mg, 10% yield) and 10 (111 mg, 50% yield) as yellow-orange 
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solids. (9) mp 89-91 °C. 1H NMR (400 MHz, CDCl3) δ: 1.67 (s, 3H), 1.79 (s, 3H), 3.32 (d, J = 
7.1 Hz, 2H), 3.49 (s, 3H), 3.93 (s, 6H), 5.21-5.23 (m, 1H), 5.27 (s, 2H), 6.24 (s, 1H), 6.97 (dd, 
JH-F = 8,5 Hz, JH-H = 8,5 Hz, 1H), 7.28-7.31 (m, 1H), 7.36 (dd JH-F = 12.2 Hz, JH-H = 2.0 Hz, 1H), 
7.68 (d, J = 15.6 Hz, 1H), 7.74 (d, J = 15.6 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 17.9, 21.8, 
25.9, 56.0, 56.4, 56.4, 89.3, 94.1, 107.2, 111.1, 113.3, 114.6 (d, 2JC-F = 18.5 Hz), 122.8, 126.1, 
126.9, 129.1, 131.4, 140.9, 149.4, 152.6 (d, 1JC-F = 246.6 Hz), 161.0, 161.2, 164.4, 193.0. 19F 
NMR (376 MHz, CDCl3) δ: -134.56. Elemental Analysis for C24H27FO6 calculated: % C, 66.96; 
% H, 6.32; found: % C, 66.71; % H, 6.04. (10) mp 163-165 °C. 1H NMR (400 MHz, Acetone-d6) 
δ: 1.63 (s, 3H), 1.76 (s, 3H), 3.28 (d, J = 7.2 Hz, 2H), 3.93 (s, 3H), 3.95 (s, 3H), 5.23-5.26 (m, 
1H), 6.15 (s, 1H), 7.20 (dd JH-F = 8.6 Hz, JH-H = 8.5 Hz, 1H), 7.48-7.51 (m, 1H), 7.54 (dd JH-F = 
12.1 Hz, JH-H = 2.1 Hz, 1H), 7.69 (d, J = 15.5 Hz, 1H), 7.90 (d, J = 15.5 Hz, 1H), 9.23 (s, 1H). 
13C NMR (100 MHz, Acetone-d6) δ: 17.8, 22.0, 25.8, 56.2, 56.6, 91.6, 106.3, 108.8, 114.5, 
115.3, 115.5, 123.9, 126.9, 127.6, 129.7, 131.0, 141.4, 154.4, 161.9, 163.0, 166.3, 193.0. 19F 
NMR (376 MHz, CDCl3) δ: -135.91. Elemental Analysis for C22H23FO5 calculated: % C, 68.38; 
% H, 6.00; found: % C, 68.44; % H, 5.85. 
4.18. (E)-3-(2-fluoro-4-methoxyphenyl)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)-3-
(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one (12) and (E)-1-(2,4-dihydroxy-6-methoxy-3-
(3-methylbut-2-en-1-yl)phenyl)-3-(2-fluoro-4-methoxyphenyl)prop-2-en-1-one (13). 
The title compounds were prepared according the general procedure, starting from compound 11 
(100 mg, 0.21 mmol). The residue was purified by silica gel flash chromatography (n-
hexane/EtOAc 7:1) to afford 12 (41 mg, 45% yield) as orange solid and 13 (15 mg, 18% yield) 
as yellow-orange amorphous solid. (12) mp 94-96 °C. 1H NMR (400 MHz, CDCl3) δ: 1.66 (s, 
3H), 1.78 (s, 3H), 3.31 (d, J = 7.1 Hz, 2H), 3.48 (s, 3H), 3.83 (s, 3H), 3.89 (s, 3H), 5.19-5.23 (m, 
 
26
1H), 5.25 (s, 2H), 6.22 (s, 1H), 6.64 (dd, JH-F = 12.5 Hz, JH-H = 2.5 Hz, 1H), 6.72 (dd, J1 = 8.6 Hz, 
J2 = 2.5 Hz, 1H), 7.49 (dd, JH-F = 8.7 Hz, JH-H = 8.6 Hz, 1H), 7.80 (d, J = 15.8 Hz, 1H), 7.87 (d, J 
= 15.8 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 17.9, 21.8, 25.9, 55.8, 55.9, 56.3, 89.3, 94.1, 
102.1 (d, 2JC-F = 26.0 Hz), 107.3, 110.8, 111.1, 116.6, 122.9, 128.1, 130.8, 131.4, 135.2, 161.0, 
162.4, 162.5, 162.9 (d, 1JC-F = 254.4 Hz), 164.4, 193.3. 19F NMR (376 MHz, CDCl3) δ: -110.93. 
Elemental Analysis for C24H27FO6 calculated: % C, 66.96; % H, 6.32; found: % C, 67.15; % H, 
6.06. (13) 1H NMR (400 MHz, Acetone-d6) δ: 1.65 (s, 3H), 1.77 (s, 3H), 3.30 (d, J = 7.1 Hz, 
2H), 3.91 (s, 3H), 3.93 (s, 3H), 5.23-5.26 (m, 1H), 6.83 (dd, JH-F = 12.8 Hz, JH-H = 2.5 Hz, 1H), 
6.88 (dd, J1 = 8.4 Hz, J2 = 2.5 Hz, 1H), 7.74-7.78 (m, 1H), 7.85 (d, J = 15.7 Hz, 1H), 8.02 (d, J = 
15.7 Hz, 1H) 9.03 (br, 1H). 13C NMR (100 MHz, Acetone-d6) δ: 16.9, 21.1, 24.9, 55.2, 55.4, 
90.8, 101.6 (d, 2JC-F = 26.0 Hz), 105.4, 108.0, 111.2, 115.8, 122.9, 127.5, 130.1, 130.2, 133.8, 
161.0, 162.5 (d, 1JC-F = 252.0 Hz), 162.7, 162.8, 165.5, 192.2. 19F NMR (376 MHz, CDCl3) δ: -
114.07. Elemental Analysis for C22H23FO5 calculated: % C, 68.38; % H, 6.00; found: % C, 
68.49; % H, 6.31. 
4.19. (E)-1-(2-hydroxy-6-methoxy-4-(methoxymethoxy)-3-(3-methylbut-2-en-1-
yl)phenyl)-3-(4-nitrophenyl)prop-2-en-1-one (14)  
Starting from compound 23 (274 mg, 0.58 mmol) and following the general procedure, MOM 
mono-protected derivative 14 was obtained as the only reaction product. The residue was 
purified by flash chromatography (n-hexane/EtOAc 7:1) using a Isolute Flash Si II cartridge to 
afford 14 (191mg, 77% yield) as yellow-orange solids, mp 125-127 °C. 1H NMR (400 MHz, 
CDCl3) δ: 1.67 (s, 3H), 1.79 (s, 3H), 3.33 (d, J = 7.1 Hz, 2H), 3.50 (s, 3H), 3.94 (s, 3H), 5.19-
5.25 (m, 1H), 5.28 (s, 2H), 6.26 (s, 1H), 7.70-7.74 (m, 3H), 7.94 (d, J = 15.7 Hz, 1H), 8.24-8.27 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ: 17.9, 21.7, 25.9, 56.1, 56.4, 89.3, 94.1, 107.1, 111.3, 
 
27
122.6, 124.3, 128.8, 131.6, 132.1, 138.5, 142.1, 148.3, 161.1, 161.7, 164.5, 192.5. Elemental 
Analysis for C23H25NO7 calculated: % C, 64.63; % H, 5.90; % N, 3.28; found: % C, 64.47; % H, 
5.77; % N, 3.44. 
4.20. Cell culture 
Human umbilical vein endothelial cells (HUVECs) were purchased by PromoCell (Heidelberg, 
Germany) and cultured in endothelial cell growth medium-2 (EGM-2) (Lonza, Basel, 
Switzerland) containing 10% FBS, 1% L-glutamine 2 mM and 1% Penicillin/Streptomycin 
(Sigma-Aldrich, Milan, Italy). Cells were treated with XN (Sigma-Aldrich, Milan, Italy) and its 
derivatives dissolved in DMSO in a stock solution of 20 mM and used at indicated 
concentrations for different time periods. In all biological assays XN was used as positive 
control. 
4.21. Cell Proliferation assay 
The effect of XN and its derivatives on HUVE cell proliferation was determined by 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma Aldrich) assay. Briefly, 1 x 
103 cells were seeded into 96-well plates and incubated at 37 °C overnight. Cells were then 
treated with XN and its derivative with different concentrations ranging from 1 M to 20 M 
and incubated for 24, 48, 72 or 96 h. Control cells (CTRL) received EGM-2 medium containing 
10% FBS, 1% L-glutamine 2 mM and 1% Penicillin/Streptomycin with dissolved vehicle 
(DMSO). MTT reagent 5 (mg/mL) was added to cell cultures and incubated for 3 hours at 37 °C. 
After incubation, medium was replaced with 100 μL of DMSO and the amount of solubilized 
formazan was quantified at 540 nm in a SpectraMax M2 (Molecular Devices, Sunnyvale CA). 
4.22. Determination of apoptosis by Flow Cytometry 
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HUVECs (2 x 105 cells/well) were treated with increasing concentrations of XN and its synthetic 
derivatives (ranging from 5 µM to 20 µM) for 24h. Control cells received EGM-2 medium 
containing 10% FBS, 1% L-glutamine 2 mM and 1% Penicillin/Streptomycin with dissolved 
vehicle (DMSO). Cells were then collected and stained with FITC-conjugated Annexin V (BD: 
Becton Dickinson Bioscences, San Jose, CA) and 7-AAD (BD). Untreated cells and those treated 
with DMSO (vehicle) were used as control. This method allows discrimination between viable 
cells (Annexin V negative, 7-AAD negative) and apoptotic cells (Anexin V positive, 7-AAD 
positive/negative). Analysis was performed on 20000 gated cells, excluding cell debris, using a 
FACSCanto II (BD), with excitation set at 488 nm and emission at 518 nm (FITC detector) or 
620 nm (PE fluorescence detector). 
4.23. Cell adhesion assay in vitro 
HUVECs (3x103 cells) were treated with XN and its derivatives (10 µM) and seeded in a 48 
wells plate pre-coated for 45 min with fibronectin (2 µg/mL). Control cells received EGM-2 
medium containing 10% FBS, 1% L-glutamine 2 mM and 1% Penicillin/Streptomycin with 
dissolved vehicle (DMSO). After 90 min incubation, the supernatants were removed and cells 
were washed with PBS. Cells were then fixed with 4% paraformaldehyde and stained with 
DAPI. Six different replicates for each condition were considered. Eighteen microscope fields 
were randomly selected from the six wells for each treatment to count the number of adherent 
cells. 
4.24. HUVEC migration and invasion in vitro assays 
Chemoinvasion and chemotaxis assays were performed in modified Boyden chambers, as 
previously described [25, 26]. Briefly, viable HUVE cells (5 x 104) were seeded in the upper 
compartment of the Boyden chamber and treated with XN and its derivatives (10 µM) for 6 h 
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and 24 h respectively for migration and invasion in vitro assays. Control cells received EGM-2 
medium containing 10% FBS, 1% L-glutamine 2 mM and 1% Penicillin/Streptomycin with 
dissolved vehicle (DMSO). Chemoattractant (FBS 10%) in EGM-2 was added in the lower 
compartment. 10 µm pore-size polycarbonate filters were pre-coated with collagen IV (50 
µg/mL, Sigma Aldrich) for the chemotaxis assay and matrigel (1 mg/mL, BD) for the 
chemoinvasion assay. After 6 h (chemotaxis) or 24 h (chemoinvasion) of incubation, filters were 
recovered and migrated or invaded cells on the lower filter surface were fixed with absolute 
ethanol and stained with DAPI. Viable cells were counted in a double-blind manner in 5 
consecutive fields each with a Zeiss Microscope associated with a Nikon camera. Experiments 
were performed in triplicate.  
 
4.25. Morphogenesis assay 
2,5x104 HUVE cells were seeded on a 10 mg/mL matrigel pre-coated 96-well plate and treated 
with XN and its derivatives (10 µM) for 6 h at 37 °C and 5% CO2. Control cells received EGM-2 
medium containing 10% FBS, 1% L-glutamine 2 mM and 1% Penicillin/Streptomycin with 
dissolved vehicle (DMSO). After 6 h, the network formation was detected with an inverted 
microscope (Zeiss). Master segment numbers and length, meshes numbers and area were 
quantified using ImageJ software and the Angiogenesis Analyzer tool 27]. Four to five different 
replicates were used for each experiment. Cells treated with Serum free medium (SFM), media 
containing DMSO (vehicle) and media containing 10% FBS (FBS 10%) were used as controls.  
4.26. Statistical Analyses 
Flow cytometry analyses were performed using BD FACSDiva (v6.1.2) software. For the 
morphogenesis analysis, master segment length and, mesh numbers and areas were quantified 
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using the ImageJ software and the Angiogenesis Analyzer tool. Statistical analyses were 
performed using the GraphPad Prism 5 statistics and graphing program (GraphPad Software, San 
Diego, CA). One-way ANOVA with Dunnett's Multiple Comparison Test were used to compare 
multiple data sets.  
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Figure captions 
Fig. 1. Natural product Xanthohumol (XN) and its new synthetic analogues. 
Figure 2. Effects of XN derivatives on endothelial cell proliferation in vitro –XN and XN 
derivatives interfere with endothelial cell (HUVEC) proliferation, as assessed by MTT assay. 
Results are showed as Mean  SEM; *p <0.05, ***p<0.001 compared to XN alone. “Vehicle” 
indicates cells treated with vehicle (DMSO in the medium). 
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Figure 3. Effects of XN derivatives on endothelial cell viability in vitro - Flow cytometry 
analysis showed that 24 h treatment of endothelial cells with 20 µM XN derivatives resulted in 
increased rates of apoptotic (AnnexinV+7-AAD-/+) cells. “Vehicle” indicates cells treated with 
vehicle (DMSO in the medium). Results are showed as Mean  SEM.  
Figure 4. Effects of xanthohumol derivatives on HUVE cell adhesion, invasion and 
migration. XN and XN derivatives at 10 µM concentration can interfere with crucial steps of 
angiogenesis by decreasing HUVEC A) adhesion B) migration and C) invasion, as compared to 
vehicle-treated cells. “Vehicle” indicates cells treated with vehicle (DMSO in the medium). 
Results are showed as Mean  SEM. *p <0.05; **p<0.001; ***p<0.001 as indicated by the bars.  
 
Figure 5. Effects of XN derivatives on HUVEC morphogenesis – Following 6 h treatment, 
XN and all XN derivatives at 10 µM concentration can inhibit HUVEC ability to form capillary-
like structures on matrigel compared with vehicle-treated cells. SFM: cells treated with serum-
free EGM-2 medium as a negative control. FBS 10%: cells treated with medium containing 10% 
FBS without vehicle. “Vehicle” indicates cells treated with vehicle (DMSO in the medium). 
Results are showed as Mean  SEM. *p <0.05; **p<0.001; ***p<0.001 as indicated by the bars. 
 
 
 
